Though headlines had indicated that a Roundup cancer settlement had been reached, there is now news that a portion of the proposed agreement is being discarded following significant skepticism voiced by the federal judge overseeing the case.
Though U.S. District Judge Vince Chhabria seems amenable to a portion of the $10 billion agreement, he signaled that a portion of the proposal that assigned $1.25 billion for resolving future lawsuits was inadequate, and particularly so because of the challenges of predicting scientific discovery or illnesses caused by a product that continues to be sold.
As the U.S. District Court for the Southern District of Florida prepares to hear the consolidated Zantac cancer litigation cases, two additional plaintiffs have filed lawsuits claiming that the popular heartburn treatment was responsible for significant illness, and in one of the cases, the death of a family member.
In August of 2018, California school groundskeeper Dewayne “Lee” Johnson had his day in court, presenting evidence that his diagnosis of non-Hodgkin’s lymphoma was a case of Roundup cancer. After hearing testimony in the case, the jury unanimously agreed that Monsanto was responsible for his injuries and assessed the company $289 million, including $39 million in compensatory damages and $250 million in punitive damages.
With dozens of similar lawsuits pending against the maker of the Juul e-cigarette, the Attorney General for the state of Colorado has announced his own litigation against the vaping company, accusing them of false advertising that downplayed the health risks of its products and took advantage of its appeal to children. Phil Weiser has reportedly been building his case against the company for almost a year and has now filed it in Denver District Court.
Patients who had spent years taking a popular bladder pain medication were recently made aware of their potential for Elmiron vision loss after news reports and a warning label being added to the drug’s packaging. Now a new article in the respected Journal of the American Medical Association Opthalmology has given even more reason for concern, as it reports data that suggests the risk for vision loss can continue long after their use of the drug has stopped.
There is a growing chorus of voices rising against the manufacturer of Juul e-cigarettes, accusing the company of negligently marketing their electronic vaping devices to adolescents. Citing testimony provided to Congress about the company’s marketing campaign targeting schoolchildren, a group of five Native American tribes has joined the fight, accusing the company of specifically focusing on them and their youth.
After learning of a causal link between cancer and the popular heartburn medication Zantac, people diagnosed with various forms of the disease have begun filing lawsuits against the drug’s manufacturers, and a rapidly growing multidistrict litigation has begun to take shape.
At the same time that Bayer AG has agreed to a $10 billion settlement with victims of Roundup cancer, a federal judge in California delivered a controversial ruling favoring the weed killer’s manufacturer, allowing them to sell the product in the state without being required to label their product as carcinogenic.
As evidence continues to mount linking Juul e-cigarettes to serious lung injuries, complications, and addiction, the American Cancer Society has reported continuing growth in sales of the company’s products, even in the face of the company taking actions to discontinue the sales of products that have been most popular with teens.
On June 8th, Jerry Bentley of Kentucky submitted a personal injury lawsuit accusing Boehringer Ingelheim Pharmaceuticals, Inc. of Ridgefield Connecticut of being responsible for his Zantac cancer. Mr. Bentley indicates that he has been using the popular heartburn medication daily since the year 2000, and did not stop until 2018 when he learned of the medication’s potential dangers.
Danziger & De Llano, LLP. Office Locations: (Principal Office) Houston, Texas . Contact Danziger & De Llano for more information. Prior results do not guarentee or predict a similar outcome with respect to any future matter.